How do you take insulin?
| Product | Strength | Containers |
|---|---|---|
| Humulin R | 100 units/mL (U-100) | 10 mL and 3 mL multiple-dose vials1 |
| Humalog | 100 units/mL (U-100), also 200 units/mL (U-200) | U-100: 10 mL and 3 mL multiple-dose vials, 3 mL cartridges and prefilled pens; U-200: prefilled pens only2 |
| Novolog | 100 units/mL (U-100) | 10 mL multiple-dose vial; 3 mL FlexPen and FlexTouch prefilled pens; 3 mL PenFill prefilled cartridges3 |
| Humulin N | 100 units/mL (U-100), white cloudy suspension | 10 mL multiple-dose vial and 3 mL KwikPen4 |
How insulin is supplied
The table is set at the top of the page
The Humalog and Humulin R vial cartons say to use only a U-100 syringe.21 The Humalog label says the dose window of its U-100 or U-200 prefilled pens shows the insulin units to be delivered and no conversion is needed; the Humulin N label says its KwikPen dials in 1 unit increments.24
Mixing and diluting
The Humulin R label says to mix it only with Humulin N, drawing Humulin R into the syringe first, and its leaflet says to inject immediately after mixing.1 The Humalog U-100 and Novolog labels allow mixing with NPH insulin only, drawn first and injected immediately.23
When and where it is injected
| Label | Timing | Sites |
|---|---|---|
| Humulin R | Subcutaneous, approximately 30 minutes before meals | Thigh, upper arm, abdomen or buttocks1 |
| Humalog U-100 or U-200 | Subcutaneous, within 15 minutes before a meal or immediately after a meal | Abdominal wall, thigh, upper arm or buttocks2 |
| Novolog | Subcutaneous, within 5-10 minutes before a meal | Abdominal area, thigh, buttocks or upper arm3 |
The Humulin R label says to rotate sites within the same region to reduce the risk of lipodystrophy and localized cutaneous amyloidosis, and not to inject into areas of either.1
Dose, regimens and adjustment
The Humulin R, Humalog, Humulin N and Novolog labels give no fixed starting dose; each says to individualize the dosage by metabolic needs, blood glucose monitoring results and glycemic control goal, all but Humulin N also by route of administration.1243 None of the four labels searched gives a stepping scheme; the Humulin N label lists changes that may need a dosage adjustment: physical activity, meal patterns, renal or hepatic function, or acute illness.4
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| Pre-Mix Insulin Lispro Treatment for Type 2 Diabetes Patients Who Consume a Light Breakfast (NCT00664534, Eli Lilly and Company, 2008) | Comparator arm: glargine with or without 1, 2 or 3 lispro injections; experimental arm: mid- or low-mixture premixed lispro, 1, 2 or 3 injections; both plus oral medicines, doses set by patient glucose level5 | 344 participants with type 2 diabetes with inadequate glycemic control on oral therapy | 48 weeks |
| Diabetes Control and Complications Trial (DCCT Research Group, 1993) | Intensive: an external insulin pump or three or more daily injections, guided by frequent blood glucose monitoring; conventional: one or two daily injections6 | Patients with insulin-dependent diabetes mellitus | Followed a mean 6.5 years |
Storage
The labels differ on how many days each product keeps at room temperature, which all four storage tables give as up to 86°F (30°C).1423
| Product | Room temperature |
|---|---|
| Humulin R vial | 31 days in total, unopened plus in use1 |
| Humulin N | 31 days for a vial and 14 days for a KwikPen, which is not to be refrigerated in use4 |
| Humalog | 28 days in total for U-100 and U-200, which the label says not to freeze; the KwikPen 28 days in use, room temperature only2 |
| Novolog vial | 28 days unopened or in use; until the expiration date only if unopened and refrigerated3 |
Frequently asked questions
How long does insulin act in the body?
The Novolog label says that in 22 patients with type 1 diabetes the maximum glucose-lowering effect occurred between 1 and 3 hours after a subcutaneous injection of 0.15 units/kg, and gives the duration of action as 3 to 5 hours.3 The Humalog label says the time course of its glucose-lowering effect may vary between people and within the same person and depends on many conditions, including the site's blood supply and temperature.2
What safety warnings do the labels give?
The Novolog label says hypoglycemia is the most common adverse reaction of all insulins, including Novolog, and that severe hypoglycemia may be life threatening or cause death.3 The Humalog label says its prefilled pens, cartridges and reusable pens compatible with Lilly 3 mL cartridges must never be shared between patients, even if the needle is changed, and the Humulin R label says needles or syringes for its vials must never be shared with another person.21 In the Diabetes Control and Complications Trial (DCCT Research Group, 1993) of 1441 patients with insulin-dependent diabetes mellitus, the chief adverse event with intensive therapy was a two-to-threefold increase in severe hypoglycemia.6
Is there a label or trial for non-diabetic insulin use?
Searches of DailyMed, ClinicalTrials.gov and PubMed returned no label and no human trial for non-diabetic or performance use.
References
- DailyMed. These highlights do not include all the information needed to use HUMULIN R safely and effectively. See full prescribing information for HUMULIN R. HUMULIN R (insulin human) injection, for subcutaneous or intravenous use Initial U.S. Approval: 1982. 2026. dailymed.nlm.nih.gov
- DailyMed. These highlights do not include all the information needed to use HUMALOG safely and effectively. See full prescribing information for HUMALOG. HUMALOG (insulin lispro) injection, for subcutaneous or intravenous use Initial U.S. Approval: 1996. 2026. dailymed.nlm.nih.gov
- DailyMed. These highlights do not include all the information needed to use NOVOLOG safely and effectively. See full prescribing information for NOVOLOG. NOVOLOG ® (insulin aspart) injection, for subcutaneous or intravenous use Initial U.S. Approval: 2000. 2023. dailymed.nlm.nih.gov
- DailyMed. These highlights do not include all the information needed to use HUMULIN N safely and effectively. See full prescribing information for HUMULIN N. HUMULIN N (insulin isophane human) injectable suspension, for subcutaneous use Initial U.S. Approval: 1982. 2025. dailymed.nlm.nih.gov
- ClinicalTrials.gov. NCT00664534: Pre-Mix Insulin Lispro Treatment for Type 2 Diabetes Patients Who Consume a Light Breakfast. 2011. clinicaltrials.gov
- PubMed. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. 1993. pubmed.ncbi.nlm.nih.gov